Staar Surgical (STAA) is trading down at $21.61 (-3.18%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on STAA
Current price targets from 3 firms average $30.7, median $31, ranging from $28 to $33 — the average is 42% above the current $21.6. Each is tracked to its date and scored the same way a member's call is.
- Stifel $22.4 → $31 by Sep 2027 Sep 29, 2026 via Investing.com · Stifel's track record
- Piper Sandler $22.4 → $33 by Sep 2027 Sep 29, 2026 via Investing.com · Piper Sandler's track record
- Jefferies $22.4 → $28 by Sep 2027 Sep 29, 2026 via Investing.com · Jefferies's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Staar Surgical revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Jan 2020 | FY2020Jan 2021 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Jan 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $82.4M | $90.6M | $124.0M | $150.2M | $163.5M | $230.5M | $239.4M | $322.4M | $313.9M | $239.4M |
| Growth (year over year) | +6.9% | +9.9% | +36.8% | +21.2% | +8.8% | +41.0% | +3.9% | +34.7% | −2.6% | −23.7% |
| Gross profit | $58.4M | $64.3M | $91.5M | $112.0M | $118.4M | $178.6M | $223.4M | $252.7M | $239.6M | $182.4M |
| Gross margin | 70.8% | 70.9% | 73.8% | 74.5% | 72.4% | 77.5% | 93.3% | 78.4% | 76.3% | 76.2% |
| Operating income | −$12.7M | −$3.63M | $6.59M | $11.9M | $6.77M | $33.3M | $43.8M | $28.1M | −$12.6M | −$91.7M |
| Operating margin | −15.4% | −4.0% | 5.3% | 7.9% | 4.1% | 14.5% | 18.3% | 8.7% | −4.0% | −38.3% |
| Net income | −$12.1M | −$2.14M | $4.97M | $14.0M | $5.91M | $27.5M | $39.7M | $21.3M | −$20.2M | −$80.4M |
| Net margin | −14.7% | −2.4% | 4.0% | 9.4% | 3.6% | 11.9% | 16.6% | 6.6% | −6.4% | −33.6% |
| EPS (diluted) | −$0.30 | −$0.05 | $0.11 | $0.30 | $0.12 | $0.56 | $0.80 | $0.43 | −$0.41 | −$1.62 |
| Balance sheet | ||||||||||
| Cash and equivalents | $14.0M | $18.5M | $103.9M | $120.0M | $152.5M | $199.7M | $86.5M | $183.0M | $144.2M | $153.2M |
| Total assets | $65.5M | $67.9M | $167.3M | $207.5M | $257.4M | $345.8M | $418.8M | $488.7M | $509.5M | $451.7M |
| Total liabilities | $27.6M | $25.0M | $34.9M | $47.6M | $60.2M | $87.2M | $82.7M | $102.7M | $112.2M | $107.5M |
| Shareholders' equity | $37.9M | $42.9M | $132.4M | $159.9M | $197.2M | $261.6M | $336.1M | $386.0M | $397.3M | $344.2M |
| Cash flow | ||||||||||
| Operating cash flow | $1.05M | $2.85M | $12.8M | $25.8M | $21.0M | $44.0M | $35.7M | $14.6M | $15.7M | −$34.2M |
| Capital expenditure | $3.21M | $1.05M | $2.25M | $10.1M | $8.40M | $13.6M | $18.1M | $18.2M | $23.4M | $5.82M |
| Free cash flow | −$2.16M | $1.81M | $10.5M | $15.7M | $12.5M | $30.3M | $17.6M | −$3.59M | −$7.67M | −$40.0M |
| Share buybacks | — | — | — | — | — | — | — | — | — | $6.46M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Jan 2026 | Q1 FY26Apr 2026 | Q2 FY26Jul 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $88.6M | $49.0M | $42.6M | $44.3M | $94.7M | $57.8M | $93.5M | $93.5M |
| Growth (year over year) | +10.3% | −35.8% | −44.9% | −55.2% | +6.9% | +18.1% | +119.6% | +111.0% |
| Gross profit | $68.5M | $31.6M | $28.0M | $32.8M | $77.9M | $43.7M | $68.9M | $69.7M |
| Gross margin | 77.3% | 64.7% | 65.8% | 74.0% | 82.2% | 75.7% | 73.6% | 74.5% |
| Operating income | $5.68M | −$27.9M | −$57.4M | −$30.0M | $18.5M | −$22.8M | $7.98M | $10.1M |
| Operating margin | 6.4% | −57.0% | −134.8% | −67.6% | 19.5% | −39.5% | 8.5% | 10.8% |
| Net income | $9.98M | −$34.2M | −$54.2M | −$16.8M | $8.88M | −$18.3M | $5.21M | $8.06M |
| Net margin | 11.3% | −69.9% | −127.3% | −37.9% | 9.4% | −31.7% | 5.6% | 8.6% |
| EPS (diluted) | $0.20 | −$0.69 | −$1.10 | −$0.34 | $0.18 | −$0.36 | $0.10 | $0.16 |
| Balance sheet | ||||||||
| Cash and equivalents | $164.0M | $144.2M | $173.1M | $167.1M | $176.2M | $153.2M | $131.9M | $148.6M |
| Total assets | $537.6M | $509.5M | $457.4M | $437.8M | $456.4M | $451.7M | $451.1M | $475.2M |
| Total liabilities | $109.5M | $112.2M | $107.4M | $101.2M | $102.6M | $107.5M | $98.8M | $109.8M |
| Shareholders' equity | $428.1M | $397.3M | $350.0M | $336.6M | $353.8M | $344.2M | $352.4M | $365.4M |
| Cash flow | ||||||||
| Operating cash flow | $3.82M | $642.0K | −$5.73M | −$27.2M | $2.67M | −$3.91M | −$21.7M | $19.7M |
| Capital expenditure | $6.23M | $5.72M | $1.47M | $1.79M | $883.0K | $1.68M | $443.0K | $494.0K |
| Free cash flow | −$2.42M | −$5.08M | −$7.20M | −$29.0M | $1.78M | −$5.59M | −$22.1M | $19.2M |
| Share buybacks | — | — | — | — | $1.98M | $0 | — | — |
From Staar Surgical's 10-K and 10-Q filings with the SEC; its fiscal year ends in January. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Staar Surgical
- Headquarters
- Monrovia, California From SEC filings, Oct 2026
Recent News (2)
-
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA) NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ: STAA) concerning possible breaches of fiduciary duties. If …
-
Stifel upgrades STAAR Surgical stock rating on China growth outlook
Stifel upgrades STAAR Surgical stock rating on China growth outlook
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International